CoChat
Sign Up
Cited by 132Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 191 of the 193 references it cites were found in a registry or an index.

General aspects of neurodegeneration

Jellinger, K. A.·2003·Journal of Neural Transmission. Supplementa
DOI 10.1007/978-3-7091-0643-3_7
Open this paper in CoChat — free account

Abstract

Neurodegenerative diseases are morphologically featured by progressive cell loss in specific vulnerable neuronal populations of the central nervous system, often associated with cytoskeletal protein aggregates forming intracytoplasmic and/or intranuclear inclusions in neurons and/or glial cells. Most neurodegenerative disorders are now classified either according to the hitherto known genetic mechanisms or to the major components of their cellular protein inclusions. The major basic processes inducing neurodegeneration are considered multifactorial ones caused by genetic, environmental, and endogenous factors. They include abnormal protein dynamics with defective protein degradation and aggregation, many of them related to the ubiquitin-proteasomal system, oxidative stress and free radical formation, impaired bioenergetics and mitochondrial dysfunctions, and "neuroinflammatory" processes. These mechanisms that are usually interrelated in complex vitious circles finally leading to programmed cell death cascades are briefly discussed with reference to their pathogenetic role in many, albeit diverse neurodegenerative diseases, like Alzheimer disease, synucleinopathies, tauopathies, and polyglutamine disorders. The impact of protein inclusions on cell dysfunction, activation or prevention of cell death cascades are discussed, but the molecular basis for the underlying disease mechanisms remains to be elucidated.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-7091-0643-3_7

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 193 references

Research works printed but not linked: 19

  1. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552–1555 · DOI
  2. Cluskey S, Ramsden DB (2001) Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol 54: 386–392
  3. Henry JM, Jellinger KA (2003) Postencephalitic parkinsonism. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  4. Jellinger KA (2003b) Experimental models of synucleinopathies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  5. Jellinger KA, Duda J (2003) Neuroaxonal dystrophies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  6. Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  7. Lantos PL, Quinn N (2003) Dementia with Lewy bodies. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  8. Linert W, Jellinger KA (2001) Cell death mechanisms and the role of iron in neurodegeneration. In: Segura-Aquilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing, Johnson City, pp 21–65
  9. Lippa CF (2003) Lewy bodies in conditions other than disorders of α-synuclein. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  10. McGeer PL, McGeer EG (2002) Polymorphisms in inflammatory genes enhance the risk of Alzheimer disease. Alzheimer Research Forum, February 11, 2002
  11. Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V (2001) Protein aggregation. Clin Chem Lab Med 39: 1065–1075
  12. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47: 365–368 · DOI
  13. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090–3099 · DOI · Paper page
  14. Perry G, Liu Q, Wataya T, Shimohama S, Nunomura A, Siedlak SL, Sayre LL, Smith MA (2002) Neurofilament proteins are major targets of oxidative damage in the nervous system. J Neuropathol Exp Neurol 61: 456
  15. Perry G, Srinivas R, Nunomura A, Smith MA (2003) Oxidative mechanisms in neurodegenerative diseases. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)
  16. Perry G, Zhu X, Atwood CS, Numamura A, Smith MA (2002) Oxidative abnormalities as a window to Alzheimer disease. 8th International Conference on Alzheimer disease and Related Disorders, July 19–25, 2002, Abstr. # 4235
  17. Simon DK, Beal MF (2002) Pathogenesis: oxidative stress, mitochondrial dysfunction and excitotoxicity. In: Factor SA, Weiner WJ (eds) Parkinson’s disease. Diagnosis and management. Demos, New York, pp 281–290
  18. Tatton WG, Olanow CW (1999) Apoptosis in neurodegenerative disease: The role of mitochondria. Biochem Biophys Acta 1410: 195–214
  19. Trojanowski J (2003) Protein aggregation. In: Dickson DW et al (eds) Neurodegeneration and dementias. ISN Neuropathology Press, Los Angeles (in press)

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Jellinger, K. A.
Corresponding author
Jellinger, K. A.
ORCID
Jellinger, K. A.
Venue
Journal of Neural Transmission. Supplementa
Publisher
Springer Vienna
Published
2003
Issue
65
Pages
101-144
ISSN
0303-6995 (ISSN-L)
DOI
10.1007/978-3-7091-0643-3_7
OpenAlex
W48785815
Cited by
126
References
193
Citations by year
2025: 1 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 9 · 2013: 7 · 2012: 8
FWCI
39.40
Type
book chapter
Language
en
Open access
closed
Locations
  • Journal of neural transmission. Supplementum (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
neurodegeneration, neurodegenerative diseases, protein aggregation, protein inclusions, ubiquitin-proteasome system, oxidative stress, mitochondrial dysfunction, bioenergetics, neuroinflammation, programmed cell death, Alzheimer's disease, synucleinopathies, tauopathy, polyglutamine diseases, neuronal loss
MeSH terms
Animals, Inclusion Bodies, DNA, Mitochondrial, Humans, Iron, Mitochondria, Mutation, Nerve Degeneration, Nerve Tissue Proteins, Neuroglia, Neurons, Ubiquitins, Signal Transduction, Cell Death, Oxidative Stress, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review